Ensysce Biosciences, Inc. Common Stock
ENSCEnsysce Biosciences, Inc. develops innovative drug delivery technologies aimed at improving safety and efficacy in pain management and other therapeutic areas. The company focuses on creating proprietary prodrug platforms that enhance pharmacological control and reduce abuse potential of opioids and other drugs.
Company News
Ensysce Biosciences (NASDAQ: ENSC) shares surged 58.66% to $0.63 on Friday after the company announced a strategic review of alternatives aimed at enhancing shareholder value. The Board is exploring partnerships, licensing arrangements, or asset sales to advance its proprietary TAAP and MPAR platforms for safer opioid medicines.
Several companies are transitioning from strategic announcements to operational execution. Kraig Biocraft Laboratories has begun production of recombinant spider silk and received National Geographic cover feature. Rackspace and Palantir announced a strategic partnership to deploy enterprise AI in production environments. Ensysce Biosciences init...
DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developm...
Ensysce Biosciences advanced multiple clinical initiatives in Q2 2025, including launching a Phase 3 trial for PF614, completing enrollment in an overdose prevention study, and receiving a patent notice for its OUD program.
Ensysce Biosciences reported Q2 2025 results, advancing its PF614 opioid program to Phase 3 and achieving milestones in overdose-protection studies. The company reported a narrower GAAP loss of $(0.79) per share, with revenue primarily from federal grants.
